Pool's Cryoprecipitate and Exhausted Plasma in the Treatment of Von Willebrand's Disease and Factor-Xi Deficiency

Bennett, Enid; Dormandy, Katharine M.

doi:10.1016/s0140-6736(66)92985-0

Cited by 78 publications

(33 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With such a sharp distinction between the survivals of the VIII:C and the VIII R:AG (WF), it was relatively simple to correlate the latter with improvement in the ratio bleeding time and a shortening of the bleeding time. The sustained rise of VIII:C above the amount that could possibly be derived from the infusate and the more rapid decline of VIII R:AG and VIII:RWF are similar to other reports in pigs (14) and man (1,6). A number of studies in pa tients with von Willebrand's disease have also shown that the shortening of the bleeding time is much more transient than is the persistence of VIII:C after in fusions of plasma or cryoprecipitate (1, 8, 19, 25-27, 31,38).…”

Section: Discussionsupporting

confidence: 90%

Hemostatic Effect of Transfused Willebrand Factor in Porcine von Willebrand’s Disease

Bowie¹,

Fass²,

Owen³

1980

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Cryoprecipitate was infused into pigs with severe von Willebrand’s disease, and the bleeding time was corrected when the plasmatic level of VIII R:AG (WF) was above 30 U/dl. The VIII R:AG (WF) was not completely recovered but none was found in the plasma or endothelial cells. A new method for measuring the bleeding time is described -the ratio bleeding time. These results in pigs are compared with the reported results in humans.

show abstract

Section: Discussionsupporting

confidence: 90%

Hemostatic Effect of Transfused Willebrand Factor in Porcine von Willebrand’s Disease

Bowie¹,

Fass²,

Owen³

1980

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

show abstract

Section: °Cmentioning

confidence: 99%

“…In October of 1966, three patients with vWD were reported to have successfully received CRYO (Bennett & Dormandy, 1966). In the same year, Bennett and Dormandy reported on the successful use of "exhausted" plasma for a patient with factor XI deficiency (Bennett & Dormandy, 1966). Subsequently to the first positive experiences with the product, in January of 1967, Barrett and colleagues reported on the successful use of cryoprecipitate for hemophilia in 7 patients (Barrett et al, 1967).…”

Section: °Cmentioning

confidence: 99%

Cryoprecipitate transfusion: assessing appropriateness and dosing in trauma

Nascimento¹,

Rizoli²,

Rubenfeld³

et al. 2011

Transfusion Medicine

View full text Add to dashboard Cite

Cryoprecipitate is commonly used outside guidelines. In trauma, the appropriate cryoprecipitate dose and its impact on plasma fibrinogen levels are unclear.This retrospective study aims to evaluate: (1) the appropriateness of cryoprecipitate transfusion in trauma; and (2) the plasma fibrinogen response to cryoprecipitate transfusion during massive transfusion in trauma.Fibrinogen levels of < 1.0 g/L within 2 and 6 hours of cryoprecipitate transfusion were used for assessing appropriateness. Out of 394 events, 238 (60%) and 259 (66%) were considered appropriate using 2 and 6 hour criteria, respectively. A dose of 8.7 (±1.7) units caused a mean increase in fibrinogen levels of 0.55 (±0.24) g/L, or 0.06g/L per unit.In our hospital, where transfusion guidelines and policies for rapid blood product and laboratory turnaround times exist, it is possible to achieve high rates of appropriateness for cryoprecipitate transfusion in trauma. The current recommended dose causes a modest increase in fibrinogen levels.iii

show abstract

“…The first concentrate to be used for replace ment in vWD was fraction 1-0 (AHF-Kabi), which became available in Sweden in the mid1950s [6], Later, cryoprecipitate was more generally used throughout the world [7], Both these products, which are characterized by a vWF multimeric pattern very similar to that in normal plasma and FVIILC, have been found to correct both prolonged bleeding time and FVIII deficiency. Until recently, replace ment therapy in vWD was mainly based on these two products, as high-purity commercial FVIII concentrates generally fail to correct the bleeding defect in vWD and lack the large vWF multimers [8].…”

Section: Replacement Therapy In Vwdmentioning

confidence: 99%

Plasma Product Treatment in Various Types of von Willebrand’s Disease

Berntorp¹

1994

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Four different virus-inactivated factor VIII concentrates (Haemate P, Behring; Profilate, Alpha, FVIII-VHP-vWF, CRTS), near-pure von Willebrand factor (Facteur Willebrand, CRTS) or one recombinant FVIII preparation (Recombinate, Baxter) were given to one or more patients with different forms of von Willebrand’s disease. Duke bleeding time, VIII:C, vWF:Ag, RCof activity, and the multimeric pattern of plasma vWF were monitored. Both Duke bleeding time and the multimeric pattern were normalized after treatment with Haemate P, FVIII-VHP-vWF, or Facteur Willebrand, and to a lesser extent after Profilate. Except in one case, the reduction in bleeding time lasted longer after Haemate P than after the other concentrates. Recombinate had no effect on primary hemostasis, and the half-life of VIII:C was very short. If prompt hemostasis is required, and when pharmacological correction of the defect is impossible, we recommend a concentrate containing both FVIII and the full complement of vWF multimers, but for prophylactic treatment pure von Willebrand factor may be used.

show abstract

Pool's Cryoprecipitate and Exhausted Plasma in the Treatment of Von Willebrand's Disease and Factor-Xi Deficiency

Cited by 78 publications

References 2 publications

Hemostatic Effect of Transfused Willebrand Factor in Porcine von Willebrand’s Disease

Hemostatic Effect of Transfused Willebrand Factor in Porcine von Willebrand’s Disease

Cryoprecipitate transfusion: assessing appropriateness and dosing in trauma

Plasma Product Treatment in Various Types of von Willebrand’s Disease

Contact Info

Product

Resources

About